Drugs / allogeneic GM-CSF-secreting breast cancer vaccine
allogeneic GM-CSF-secreting breast cancer vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00093834 | Jan 2004 → Aug 2008 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00971737 | Jul 2009 → Mar 2016 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00847171 | Dec 2008 → Jun 2013 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00399529 | Sep 2006 → Feb 2010 | breast neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic GM-CSF-secreting breast cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00847171 ↗ |
| Action | Deplete | “Vaccines made from a person's tumor cells may make the body build an immune response to kill tumor cells.” NCT00093834 ↗ |
| Modality | Vaccine | “allogeneic GM-CSF-secreting breast cancer vaccine” NCT00093834 ↗ |
| Route | Other | “intradermally (ID)” NCT00093834 ↗ |
| Target | ERBB2 | “pieces of a protein antigen (HER-2/neu) that is delivered by the breast cancer vaccine” NCT00399529 ↗ |